Cellosaurus logo
expasy logo

Cellosaurus BxPC-3 XL-2 (CVCL_E4N9)

[Text version]
Cell line name BxPC-3 XL-2
Synonyms XL-2
Accession CVCL_E4N9
Resource Identification Initiative To cite this cell line use: BxPC-3 XL-2 (RRID:CVCL_E4N9)
Comments Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI_72317; Carbozantinib (Cometriq).
Derived from site: In situ; Pancreas; UBERON=UBERON_0001264.
Sequence variations
  • Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
  • Gene deletion; HGNC; HGNC:6770; SMAD4; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val487_Pro492delinsAla (c.1460_1474delGTGTAGGTGCTGTCA); Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; HGNC:6407; KRAS; None_reported; -; Zygosity=- (from parent cell line).
  • Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line).
Disease Pancreatic ductal adenocarcinoma (NCIt: C9120)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_E4N8 (BxPC-3 XL-1)
Children:
CVCL_E4NA (BxPC-3 XL-3)
Sex of cell Female
Age at sampling 61Y
Category Cancer cell line
Publications

PubMed=23661005; DOI=10.1038/cddis.2013.158; PMCID=PMC3674365
Hage C., Rausch V., Giese N.A., Giese T., Schonsiegel F., Labsch S., Nwaeburu C.C., Mattern J., Gladkich J., Herr I.
The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer.
Cell Death Dis. 4:e627.1-e627.10(2013)

Entry history
Entry creation19-Dec-2024
Last entry update19-Dec-2024
Version number1